China Universal Asset Management Co. Ltd. Has $125,000 Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

China Universal Asset Management Co. Ltd. grew its position in Humacyte, Inc. (NASDAQ:HUMA) by 64.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,955 shares of the company’s stock after buying an additional 8,965 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Humacyte were worth $125,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in HUMA. nVerses Capital LLC bought a new stake in shares of Humacyte in the second quarter worth about $28,000. Principal Financial Group Inc. bought a new stake in Humacyte during the 2nd quarter worth approximately $83,000. Profund Advisors LLC acquired a new stake in Humacyte during the 2nd quarter worth approximately $97,000. XTX Topco Ltd bought a new position in Humacyte in the second quarter valued at approximately $110,000. Finally, Anson Funds Management LP acquired a new position in shares of Humacyte in the first quarter valued at approximately $156,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Stock Down 1.9 %

HUMA stock opened at $5.05 on Friday. The company has a market cap of $602.72 million, a price-to-earnings ratio of -4.01 and a beta of 1.45. Humacyte, Inc. has a twelve month low of $1.96 and a twelve month high of $9.97. The business has a 50 day moving average price of $5.61 and a two-hundred day moving average price of $6.04. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Analysts anticipate that Humacyte, Inc. will post -1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on HUMA shares. TD Cowen reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.00.

Insider Activity

In related news, CEO Laura E. Niklason sold 277,090 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the sale, the chief executive officer now directly owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Laura E. Niklason sold 157,704 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now directly owns 3,519,558 shares of the company’s stock, valued at $19,076,004.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the sale, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 in the last quarter. Company insiders own 11.20% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.